{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:51Z","timestamp":1790205531989,"version":"4.1.0"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9567-17","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T22:10:06Z","timestamp":1512684606000},"page":"939-946","source":"Crossref","is-referenced-by-count":20,"title":["A Phase I\/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma"],"prefix":"10.2169","volume":"57","author":[{"given":"Masaki","family":"Ri","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[{"name":"Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Nippon Kayaku Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Nippon Kayaku Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145, 2013."},{"key":"2","unstructured":"2. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 25: 107-112, 2011."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110: 3557-3560, 2007.","DOI":"10.1182\/blood-2006-08-036947"},{"key":"4","unstructured":"4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005."},{"key":"5","unstructured":"5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007."},{"key":"6","unstructured":"6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133-2142, 2007."},{"key":"7","first-page":"3085","volume":"125","author":"AK Nooka","year":"2015","unstructured":"7. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood 125: 3085-3099, 2015.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"8","unstructured":"8. Yano H, Kayukawa S, Iida S, et al. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. Cancer Sci 99: 2309-2314, 2008."},{"key":"9","unstructured":"9. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 63: 184-192, 2011."},{"key":"10","unstructured":"10. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27: 2569-2589, 2010."},{"key":"11","unstructured":"11. Miyazaki O, Sekine K, Nakajima N, et al. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model. Int J Cancer 134: 218-223, 2014."},{"key":"12","unstructured":"12. Hamaguchi T, Doi T, Eguchi-Nakajima T, et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16: 5058-5066, 2010."},{"key":"13","unstructured":"13. Burris HA, Infante JR, Anthony Greco F, et al. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. Cancer Chemother Pharmacol 77: 1079-1086, 2016."},{"key":"14","unstructured":"14. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in Phase I cancer clinical trial. J Natl Cancer Inst 101: 708-720, 2009."},{"key":"15","unstructured":"15. Takahashi A, Ohkohchi N, Yasunaga M, et al. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases. Clin Cancer Res 16: 4822-4831, 2010."},{"key":"16","unstructured":"16. Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66: 10048-10056, 2006."},{"key":"17","unstructured":"17. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21: 325-330, 2010."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/7\/57_9567-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T03:50:43Z","timestamp":1523073043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/7\/57_9567-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9567-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}